{
  "Source": "solidot",
  "Title": "35 家仿制药制造商与 MPP 签署协议生产辉瑞抗病毒复制药物",
  "Link": "https://www.solidot.org/story?sid=70982",
  "Content": "\u003cdiv class=\"p_mainnew\"\u003e\n\t\t\t\t\t匿名读者 写道\u003ci\u003e \u0026#34;\u003ca href=\"https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and\" target=\"_blank\"\u003e药品专利池\u003c/a\u003e（Medicines Patent Pool，MPP）宣布与 35 家公司签署协议生产辉瑞 COVID-19 口服治疗药物\u003ca href=\"https://www.nmpa.gov.cn/yaowen/ypjgyw/20220212085753142.html\" target=\"_blank\"\u003e奈玛特韦片\u003c/a\u003e（nirmatrelvir）。\n\u003c/i\u003e\n\u003cp\u003e\u003ci\u003e根据药品专利池与辉瑞达成的自愿许可协议，只要新冠疫情仍被世界卫生组织列为国际关注的突发公共卫生事件，就将\u003ca href=\"https://www.solidot.org/story?sid=69645\" target=\"_blank\"\u003e免除\u003c/a\u003e协议涵盖的所有国家药物销售的特许权使用费。 \u0026#34;\u003c/i\u003e\u003c/p\u003e\t\t\t\t\t                \u003c/div\u003e",
  "Date": "2022-03-18T01:51:59Z",
  "Author": "WinterIsComing"
}